Total Payments
$381,671
2024 Payments
$225,937
Companies
21
Transactions
270
Medicare Patients
727
Medicare Billing
$53,661
Payment Breakdown by Category
Consulting$271,116 (71.0%)
Other$45,830 (12.0%)
Travel$38,409 (10.1%)
Research$20,867 (5.5%)
Food & Beverage$5,449 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $271,116 | 55 | 71.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,830 | 17 | 12.0% |
| Travel and Lodging | $38,409 | 61 | 10.1% |
| Unspecified | $20,867 | 63 | 5.5% |
| Food and Beverage | $5,449 | 74 | 1.4% |
Payments by Type
General
$360,804
207 transactions
Research
$20,867
63 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $160,263 | 125 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $54,159 | 12 | $0 (2024) |
| SANOFI US SERVICES INC. | $29,772 | 21 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $24,497 | 30 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20,812 | 9 | $0 (2024) |
| F. Hoffmann-La Roche AG | $20,435 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $16,806 | 10 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $14,833 | 5 | $0 (2023) |
| Merck Sharp & Dohme LLC | $12,253 | 15 | $0 (2024) |
| AstraZeneca UK Limited | $8,008 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225,937 | 168 | GENZYME CORPORATION ($82,705) |
| 2023 | $86,489 | 57 | GENZYME CORPORATION ($59,035) |
| 2022 | $31,944 | 13 | GENZYME CORPORATION ($18,490) |
| 2021 | $31,119 | 12 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,462) |
| 2019 | $5,634 | 15 | GlaxoSmithKline, LLC. ($4,550) |
| 2018 | $464.14 | 4 | GlaxoSmithKline, LLC. ($268.00) |
| 2017 | $82.50 | 1 | PneumRx, Inc ($82.50) |
All Payment Transactions
270 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| 11/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 11/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 11/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 11/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 11/17/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $21,698.00 | General |
| Category: Immunology | ||||||
| 11/17/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $112.00 | General |
| Category: Immunology | ||||||
| 11/17/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $112.00 | General |
| Category: Immunology | ||||||
| 11/17/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $85.12 | General |
| Category: Immunology | ||||||
| 11/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy • Category: Immunology | ||||||
| 11/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $80.83 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,514.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $757.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $757.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $17,866.00 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $429.20 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $143.62 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | Cash or cash equivalent | $100.30 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | Cash or cash equivalent | $24.64 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | Cash or cash equivalent | $22.53 | General |
| 10/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
| 10/09/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $295.50 | Research |
| Study: Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| 10/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | GENZYME CORPORATION | $14,750 | 36 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | GENZYME CORPORATION | $4,250 | 12 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,072 | 13 |
| Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy | GENZYME CORPORATION | $500.00 | 1 |
| Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | SANOFI US SERVICES INC. | $295.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 43 | 92 | $51,453 | $12,516 |
| 2022 | 3 | 67 | 106 | $57,042 | $14,640 |
| 2021 | 5 | 207 | 239 | $43,162 | $10,637 |
| 2020 | 5 | 410 | 446 | $65,191 | $15,869 |
Total Patients
727
Total Services
883
Medicare Billing
$53,661
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 27 | 63 | $42,840 | $9,927 | 23.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 29 | $8,613 | $2,589 | 30.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 38 | 69 | $46,920 | $11,818 | 25.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 20 | $5,940 | $1,595 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 15 | 17 | $4,182 | $1,227 | 29.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 23 | 41 | $27,880 | $7,131 | 25.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 32 | $9,504 | $2,590 | 27.3% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 70 | 70 | $1,610 | $323.42 | 20.1% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 56 | 56 | $2,128 | $297.81 | 14.0% |
| 94727 | Determination of lung volumes using gas dilution or washout | Facility | 2021 | 40 | 40 | $2,040 | $294.29 | 14.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 41 | 70 | $47,600 | $11,716 | 24.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 17 | $5,049 | $1,387 | 27.5% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2020 | 144 | 147 | $3,381 | $988.42 | 29.2% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 126 | 127 | $4,826 | $933.45 | 19.3% |
| 94727 | Determination of lung volumes using gas dilution or washout | Facility | 2020 | 85 | 85 | $4,335 | $844.05 | 19.5% |
About Dr. Surya Bhatt, MD
Dr. Surya Bhatt, MD is a Pulmonary Disease healthcare provider based in Bethlehem, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396936746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Surya Bhatt, MD has received a total of $381,671 in payments from pharmaceutical and medical device companies, with $225,937 received in 2024. These payments were reported across 270 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($271,116).
As a Medicare-enrolled provider, Bhatt has provided services to 727 Medicare beneficiaries, totaling 883 services with total Medicare billing of $53,661. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Bethlehem, PA
- Active Since 08/08/2007
- Last Updated 06/29/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1396936746
Products in Payments
- DUPIXENT (Biological) $158,783
- STIOLTO RESPIMAT (Drug) $18,285
- SHINGRIX (Biological) $4,550
- JARDIANCE (Drug) $4,200
- SPIRIVA (Drug) $1,860
- Yupelri (Drug) $1,126
- DUPIXENT (Drug) $1,105
- YUPELRI (Drug) $938.72
- ANORO (Drug) $268.00
- ZERBAXA (Drug) $150.00
- CHARTIS CATHETER (Device) $96.94
- PNEUMRX COILS (Device) $82.50
- XENOVIEW (Drug) $73.75
- DUPIXENT DUPILUMAB INJECTION (Biological) $12.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Bethlehem
Dr. Brian Burlew, Md, MD
Pulmonary Disease — Payments: $151,710
Pulmonary Disease $151,710
Dr. Alan Brau, M.d, M.D
Pulmonary Disease — Payments: $13,203
Pulmonary Disease $13,203
Mohamed Turki, Md, MD
Pulmonary Disease — Payments: $373.98
Pulmonary Disease $373.98
Courtney Dostal, Do, DO
Pulmonary Disease — Payments: $250.69
Pulmonary Disease $250.69
Dr. Livia Bratis, D.o, D.O
Pulmonary Disease — Payments: $80.12
Pulmonary Disease $80.12
Dr. Kenneth Wildrick, M.d, M.D
Pulmonary Disease
Pulmonary Disease